<DOC>
	<DOCNO>NCT00376805</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy donor natural killer ( NK ) cell infusion help stop growth tumor cell . It also help stop patient 's immune system reject donor 's cell . Giving NK cell related donor may kill tumor cell . PURPOSE : This study furthers research previous study ( MT2003-01 MT2004-25 ) determine specific preparatory regimen ( cyclophosphamide fludarabine ) could create environment infused NK cell grow effectively treat patient relapse AML . This study test previous regimen patient breast cancer .</brief_summary>
	<brief_title>Allogeneic Natural Killer ( NK ) Cells Patients With Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>We believe administration relate allogeneic ( donor ) natural killer cell along IL-2 , rather autologous natural killer cell provide effective anticancer therapy setting , wish test approach . To , select relate donor partially HLA-matched study subject , increase likelihood donor natural killer cell kill subject 's cancer cell . We also give chemotherapy drug increase subject 's tolerance donor natural killer cell . We test use donor natural killer ( NK ) cell infusion . The immune system special way see identifies cancer cell foreign agent ( like virus ) . The subject 's NK cell may attack cancer NK cell see tumor cell `` self '' ( coat cell surface identifies cell `` self '' `` non-self '' ) . We reason believe NK cell may kill cancer cell NK cell special receptor `` turn '' encounter cancer cell ( see `` self '' ) . We may able get around problem use donor NK cell . Finally , subject receive dose subcutaneous IL-2 3 time week ( 2 week ) prove safe previous study stimulate natural killer cell .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Inclusion criterion : Diagnosis metastatic breast cancer progress fail least one salvage chemotherapy regimen metastatic disease meet follow disease specific related criterion : Measureable metastatic disease per Response Evaluation Criteria In Solid Tumor ( RECIST ) bone eligible . Disease progression receive prior therapy hormonal agent ( estrogen/progesterone receptorpositive ) and/or trastuzumab ( Herceptin® ) ( HER2neu positive ) Brain metastasis allow provide stable ≥ 3 month prior treatment Related HLAhaploidentical natural killer cell donor available ( ≥ class I serologic type ) Male female Performance status 50100 % Platelet count ≥ 80,000/mm³ ( unsupported transfusion ) Hemoglobin ≥ 9 g/dL ( unsupported transfusion ) Absolute neutrophil count ≥ 1,000/mm³ ( unsupported sargramostim [ GMCSF ] filgrastim [ GCSF ] ) Creatinine ≤ 2.0 mg/dL Liver function test &lt; 5 time normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception LVEF &gt; 40 % * Pulmonary function &gt; 50 % * ( DLCO correct AND FEV_1 ) No active infection ( i.e. , afebrile , antibiotic , uninvestigated radiologic lesion ) At least 3 day since prior prednisone immunosuppressive medication No concurrent therapy cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>